Cargando…

Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions

Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is stil...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Sullivan, Hazel M, Feber, Andrew, Popat, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089274/ https://www.ncbi.nlm.nih.gov/pubmed/37056631 http://dx.doi.org/10.2147/OTT.S322242

Ejemplares similares

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Automated continuous noninvasive ward monitoring: future directions and challenges
por: Khanna, Ashish K., et al.
Publicado: (2019)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Treating chronic periodontitis: current status, challenges, and future directions
por: Shaddox, Luciana M, et al.
Publicado: (2010)

Radiomics and Radiogenomics in Pelvic Oncology: Current Applications and Future Directions
por: O’Sullivan, Niall J., et al.
Publicado: (2023)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

00005 Urine tumor DNA detects minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy
por: Chen, Kevin, et al.
Publicado: (2021)

Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions
por: Ferreira, Marcelo U., et al.
Publicado: (2020)

Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
por: Buldini, Barbara, et al.
Publicado: (2019)

Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges
por: Mussolin, Lara, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
por: Matthay, K K, et al.
Publicado: (2000)

Challenges and Future Directions
por: Chen, Hsinchun, et al.
Publicado: (2009)

Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy
por: Murray, Nigel P, et al.
Publicado: (2019)

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
por: Noori, Somayya, et al.
Publicado: (2023)

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
por: Drageset, V, et al.
Publicado: (2005)

Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer
por: Yan, Xing, et al.
Publicado: (2022)

Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer
por: Wallace, T.J., et al.
Publicado: (2014)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
por: Yap, Timothy A, et al.
Publicado: (2014)

The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy
por: Murray, Nigel P, et al.
Publicado: (2020)

Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
por: Chauhan, Pradeep S., et al.
Publicado: (2021)

Challenges and Controversies in the Surgical Treatment of Cervical Cancer: Open Radical Hysterectomy versus Minimally Invasive Radical Hysterectomy
por: Röseler, Jona, et al.
Publicado: (2021)

Minimally invasive esophagectomy: current status and future direction
por: Maas, Kirsten, et al.
Publicado: (2012)

Challenges for non-minimal Higgs searches at future colliders
por: Haber, Howard E.
Publicado: (1995)

Advances and Future Challenges of Minimally Invasive Surgery in Children
por: Pogorelić, Zenon
Publicado: (2022)

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches
por: Haslam, Karl, et al.
Publicado: (2016)

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies
por: Sánchez, Ricardo, et al.
Publicado: (2019)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Computing - challenges and future directions -
por: Campana, Simone
Publicado: (2021)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions
por: Pathak, Ranjan, et al.
Publicado: (2021)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

Correction: Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
por: Chauhan, Pradeep S., et al.
Publicado: (2021)

Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?
por: Guo, Hanfei, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Overview of phytosomes in treating cancer: Advancement, challenges, and future outlook
por: Gaikwad, Sachin S., et al.
Publicado: (2023)

Small cell lung cancer: updates and future directions
por: Pacheco, Jose M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ealoen2sj84ksir82ftb8v6hq3